Acceptable strategies for dealing with hereditary breast/ovarian cancer risk

被引：20

作者：

Eisinger, F

Reynier, CJ

Chabal, F

Luquet, C

Moatti, JP

Sobol, H

机构：

[1] INSERM,CRI4U003C,PARIS,FRANCE

[2] INSERM,U379,F-75654 PARIS 13,FRANCE

来源：

JOURNAL OF THE NATIONAL CANCER INSTITUTE | 1997年 / 89卷 / 10期

关键词：

D O I：

10.1093/jnci/89.10.731

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：731 / 731

页数：1

共 6 条

[1] REPORT OF THE INTERNATIONAL WORKSHOP ON SCREENING FOR BREAST-CANCER [J].

FLETCHER, SW ;

BLACK, W ;

HARRIS, R ;

RIMER, BK ;

SHAPIRO, S .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (20) :1644-1656

[2] TAMOXIFEN - TRIALS, TRIBULATIONS, AND TRADE-OFFS [J].

FRIEDMAN, MA ;

TRIMBLE, EL ;

ABRAMS, JS .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1994, 86 (07) :478-479

[3] TAMOXIFEN - DISEASE PREVENTION OR DISEASE SUBSTITUTION [J].

FUGHBERMAN, A ;

EPSTEIN, S .

LANCET, 1992, 340 (8828) :1143-1145

[4] BRCA1 testing in families with hereditary breast-ovarian cancer - A prospective study of patient decision making and outcomes [J].

Lerman, C ;

Narod, S ;

Schulman, K ;

Hughes, C ;

GomezCaminero, A ;

Bonney, G ;

Gold, K ;

Trock, B ;

Main, D ;

Lynch, J ;

Fulmore, C ;

Snyder, C ;

Lemon, SJ ;

Conway, T ;

Tonin, P ;

Lenoir, G ;

Lynch, H .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 275 (24) :1885-1892

[5]

*NIH CONS DEV PAN, 1995, JAMA-J AM MED ASSOC, V273, P491

[6] SCREENING IN BREAST-CANCER FAMILIES - IS IT USEFUL [J].

VASEN, HFA .

ANNALS OF MEDICINE, 1994, 26 (03) :185-190

← 1 →